The company also received tentative approval for the 5mg, 10mg, 15mg, and 25mg strengths.
Researchers sought to determine whether higher-intensity thromboprophylaxis may be necessary for reducing the risk of VTE in younger patients with multiple myeloma.
Researchers sought to determine whether salvage therapy with high-dose chemotherapy followed by ASCT would improve survival in patients with MM.
A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
Researchers sought to determine whether extramedullary lesions would be an indicator of prognosis in patients with multiple myeloma treated in the first line with bortezomib.
A single dose of cilta-cel yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Patients with fewer prior lines of therapy in which they were exposed or refractory to alkylators generally had better outcomes.
Researchers sought to determine whether therapy with carfilzomib, lenalidomide, and dexamethasone would be effective for patients with newly diagnosed multiple myeloma.
Researchers sought to determine if there would be a survival benefit with daratumumab combined with lenalidomide and dexamethasone in patients with transplant-ineligible MM.
Adding isatuximab to carfilzomib and dexamethasone also improved the depth of response.
Researchers sought to determine whether there was an association between NPDs and CAR-T therapy in patients with multiple myeloma.
After initial triple-class exposure, most patients received a combination of triple-class agents and other agents.
The median age of trial participants was 3.8 years younger than the median age of the real-world population.
Patients with active multiple myeloma may have insufficient responses to mRNA COVID-19 vaccines.
Researchers sought to determine whether ixazomib and dexamethasone would be more effective vs physician’s choice of treatment in relapsed or refractory AL amyloidosis.
Researchers sought to determine whether balancing expression of CD38 on target and effector cells may improve therapy response to daratumumab in patients with multiple myeloma.
Patients who received daratumumab were more likely to be MRD negative at 12 months and beyond.
CHIP was associated with higher rates of complete response and cytokine release syndrome.
Researchers sought to determine whether a short WBMRI protocol would reduce the length of MRI tests while maintaining high sensitivity and specificity for patients with multiple myeloma.